The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.
 
Samuel Rosner
No Relationships to Disclose
 
Joshua E. Reuss
Honoraria - AstraZeneca/MedImmune
Consulting or Advisory Role - Genentech/Roche; OncoCyte
Research Funding - Genentech/Roche (Inst); Verastem (Inst)
 
Marianna Zahurak
No Relationships to Disclose
 
Janis M. Taube
Consulting or Advisory Role - Akoya Biosciences; AstraZeneca/Merck; Bristol-Myers Squibb; Compugen; Merck
Research Funding - Akoya Biosciences (Inst); Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - image processing of multiplex IF/IHC slides (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/Merck; Bristol-Myers Squibb; Merck
 
Stephen Broderick
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
 
David Randolph Jones
Consulting or Advisory Role - AstraZeneca; Merck
 
Jamie E. Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Flame Biosciences; Genentech/Roche; Guardant Health; Janssen Oncology; Merck; Novartis; Sanofi/Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst)
 
Patrick M. Forde
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; F-Star Biotechnology; G1 Therapeutics; Genentech; ITeos Therapeutics; Janssen; Novartis; Sanofi; Surface Oncology
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals; Kyowa Hakko Kirin (Inst); Novartis (Inst)